MedPage Today

Alzheimer's Deaths Prompt FDA to Tighten Lecanemab Rules

The FDA will require earlier, additional MRI monitoring for Alzheimer's disease patients taking lecanemab (Leqembi), an amyloid-directed treatment given by IV infusion, the agency said Thursday. The ...
Seeking Alpha

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option The BLA is based on data from the ...
TMCnet

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Seeking Alpha

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE, Mass., Jan.
Nasdaq

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s "Best Inventions of 2025"

TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...
ALZFORUM

Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial

Lecanemab has been in clinical use in the U.S. for nearly two years, and in Japan for not quite a year. How is it going? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 ...
ALZFORUM

Leqembi in the Clinic: So Far, ARIA Echoes Trials

As lecanemab gains regulatory approval in more countries (see previous story), clinicians are eager to learn from the first centers to have incorporated this therapeutic antibody into their clinical ...
Hosted on MSN

What is lecanemab, the newly approved Alzheimer's drug? Can it really slow down dementia?

Lecanemab can only be used in the early stages of Alzheimer's. If you or a loved one are experiencing early signs of Alzheimer's diseases, such as consistent short-term memory loss or confusion about ...
Morningstar

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the ...

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ...
EurekAlert!

Anti-amyloid therapy does not change short-term waste clearance in Alzheimer’s

A group from Osaka Metropolitan University in Japan, led by graduate student Tatsushi Oura and Dr. Hiroyuki Tatekawa, found that treatment using the drug lecanemab to remove amyloid plaques in the ...
Morningstar

FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under ...

TOKYO and CAMBRIDGE, Mass., Jan. 25, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...